Clinical Trial Update: Doxycycline for Hereditary Hemorrhagic Telangiectasia [Phase 2]

View source ↗

Summary

This clinical trial update indicates that the Phase 2 study of doxycycline for hereditary hemorrhagic telangiectasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Doxycycline (Doxycycline)

Snippet

Sponsor: Unity Health Toronto | Conditions: Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 2 | Status: COMPLETED